ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nalbuphine

Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.

Drug pageNalbuphine: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 17, 201421 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Trevi Therapeutics184 open or runningphase 3since May 17, 2014May 17, 2014Nov 30, 2026phase 1 · NCT07946575
Lumosa Therapeuticsits history only10 open or runningphase 1since May 13, 2015May 13, 2015none ahead
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceuticalits history only10 open or runningphase 3since Apr 1, 2025Apr 1, 2025none ahead
Yung Shin Pharm. Ind.its history only10 open or runningphase 4since Jan 27, 2019Jan 27, 2019none ahead

Also a collaborator on its studies: Parexel and Davita Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 17, 2014First studies: 2 phase 3 studies in PruritusFirst studyNCT02143648, NCT02143973
  2. Jun 24, 20142 phase 3 studies in PrurigoNCT02174432, NCT02174419
  3. Feb 13, 2015Phase 1 study in Uremic PruritusNCT02373215 · 22 enrolled
  4. Dec 9, 2015Named nalbuphineINNProposed as its International Nonproprietary Name in WHO's List 114
  5. Mar 22, 2018Phase 3 study in Prurigo NodularisNCT03497975 · 353 enrolled · United States, Austria, France and more
  6. May 30, 20192 phase 1 studiesNCT04020016, NCT04018664
  7. Jul 11, 2019Phase 2 study in Idiopathic Pulmonary FibrosisNCT04030026 · 42 enrolled · United Kingdom
  8. Jul 7, 20232 phase 2 studiesNCT05964335, NCT05962151
  9. May 29, 2025Phase 1 study in Idiopathic Pulmonary FibrosisNCT07036029 · 9 enrolled · United States, United Kingdom
  10. Jun 3, 2025Phase 1 study in Healthy ParticipantsNCT07015398 · 132 enrolled · United States
  11. Mar 17, 2026Phase 1 study in Healthy ParticipantsNCT07487740 · 60 enrolled · United States
  12. Jun 22, 2026Phase 2 study in Chronic CoughNCT07671924 · 100 planned · Canada, United Kingdom
  13. Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisNCT07671911 · 306 planned · United States
  14. Oct 5, 2026Phase 3 study in Idiopathic Pulmonary FibrosisNCT07868419 · 201 planned · United States
  15. Nov 12, 2026Phase 1 study in Healthy ParticipantsNCT07946575 · 30 planned · United States

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07946575
  2. Aug 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07868419
  3. Sep 2027Primary completion: phase 2 study in Chronic CoughNCT07671924
  4. Jun 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07671911

TargetBeta

“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318

Studies

All 18 Trevi Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946575Healthy Participants · United States1RecruitingNov 30, 202630
NCT07868419Idiopathic Pulmonary Fibrosis · United States3RecruitingAug 2027201
NCT07671924Chronic Cough · Canada, United Kingdom2RecruitingSep 2027100
NCT07671911Idiopathic Pulmonary Fibrosis · United States3RecruitingJun 2028306
NCT07487740Healthy Participants · United States1CompletedMay 11, 202660
NCT07015398Healthy Participants · United States1CompletedSep 12, 2025132
NCT07036029Idiopathic Pulmonary Fibrosis · United States, United Kingdom1CompletedJun 30, 20269
NCT05964335Idiopathic Pulmonary Fibrosis · Australia, Canada, Chile and more2CompletedApr 24, 2025165
NCT05962151Chronic Cough · Canada, United Kingdom2CompletedJan 6, 202566
NCT04030026Idiopathic Pulmonary Fibrosis · United Kingdom2CompletedMay 27, 202242
NCT04020016Hepatic Impairment · United States1CompletedFeb 5, 202028
NCT04018664Opioid-Related Disorders · Canada1CompletedDec 3, 201856
NCT03497975Prurigo Nodularis · United States, Austria, France and more3CompletedMay 10, 2022353
NCT02373215Uremic Pruritus1CompletedNov 201322
NCT02174432Prurigo · Germany3CompletedSep 3, 201736
NCT02174419Prurigo · United States, Germany, Poland3CompletedAug 201662
NCT02143973Pruritus · United States3CompletedJan 2016167
NCT02143648Pruritus · United States, Poland, Romania3CompletedJul 2015373

How it is read

Names in the registry

  • “NAL ER”, 12 entries
  • “nalbuphine HCl ER”, 2 entries
  • “Nalbuphine Hydrochloride Injection”, 1 entry
  • “Nalbuphine ER”, 1 entry
  • “Nalbuphine ER Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.